Tofersen, a New Treatment for A.L.S., Reverses Symptoms for Somenews2026-05-06T16:09:19+00:00May 6th, 2026|The New York Times|
Tofersen, a New Treatment for A.L.S., Reverses Symptoms for Somenews2026-05-06T16:09:19+00:00May 6th, 2026|The New York Times|
F.D.A. Faces Upset Over Denials of New Drugsnews2026-03-05T19:26:40+00:00March 5th, 2026|The New York Times|
New Gene-Editing Strategy Could Help Development of Treatments for Rare Diseasesnews2025-11-20T00:06:22+00:00November 20th, 2025|The New York Times|
Scientists May Be Able to Make Grapefruits Compatible With Medications They Currently Interfere Withnews2025-01-10T16:36:58+00:00January 10th, 2025|The New York Times|
Drug Company to Share Revenues With Indigenous People Who Donated Their Genesnews2025-01-07T12:03:05+00:00January 7th, 2025|The New York Times|
What Drugmakers Did Not Tell Volunteers in Alzheimer’s Trialsnews2024-10-23T14:19:56+00:00October 23rd, 2024|The New York Times|
El ‘médico rural’ que transformó nuestra manera de ver la demencianews2024-09-14T09:03:22+00:00September 14th, 2024|The New York Times|
Francisco Lopera, the ‘Country Doctor’ Who Upended Our Understanding of Dementianews2024-09-11T14:07:34+00:00September 11th, 2024|The New York Times|
Study Suggests Genetics as a Cause, Not Just a Risk, for Some Alzheimer’snews2024-05-06T16:19:15+00:00May 6th, 2024|The New York Times|
